Paper

0

Document

Download

Flag content

0

Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia

Internal Medicine

Show More

Authors

Andrew Roberts,Matthew Davids

John Pagel,Brad Kahl,Soham Puvvada,John Gerecitano,Thomas Kipps,Mary Anderson,Jennifer Brown,Lori Gressick,Shekman Wong,Martin Dunbar,Ming Zhu,Monali Desai,Elisa Cerri,Sari Enschede,Rod Humerickhouse,William Wierda

+16 authors

Journal

New England Journal of Medicine

Published

Dec 6, 2015

DOI

10.1056/nejmoa1513257

Show more

Save

Tip

Document

Download

Flag content

0

Tip

Save

Document

Download

Flag content

Abstract

New treatments have improved outcomes for patients with relapsed chronic lymphocytic leukemia (CLL), but complete remissions remain uncommon. Venetoclax has a distinct mechanism of action; it targets BCL2, a protein central to the survival of CLL cells.

Paper PDF

This paper's license is marked as closed access or non-commercial and cannot be viewed on ResearchHub. Visit the paper's external site.